npj Vaccines (Oct 2022)

Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults

  • Heather Friberg,
  • Morgan Gargulak,
  • Amanda Kong,
  • Leyi Lin,
  • Luis J. Martinez,
  • Alexander C. Schmidt,
  • Robert M. Paris,
  • Richard G. Jarman,
  • Clemente Diaz,
  • Stephen J. Thomas,
  • Philippe Moris,
  • Jeffrey R. Currier

DOI
https://doi.org/10.1038/s41541-022-00537-2
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 10

Abstract

Read online

Abstract The increasing global impact of dengue underscores the need for a dengue virus (DENV) vaccine. We assessed B-cell and T-cell responses following vaccination with four formulations of a tetravalent dengue purified inactivated vaccine (DPIV) in dengue-primed and dengue-naive adults from two studies (NCT01666652, NCT01702857). Frequencies of DPIV-induced memory B cells specific to each DENV serotype remained high up to 12 months post-vaccination, and were higher in the dengue-primed than dengue-naive adults. A subsequent DPIV booster dose induced strong anamnestic B-cell responses. Multifunctional CD4+ T cells (predominantly expressing IL-2) were induced by DPIV, with higher frequencies in dengue-primed adults. DPIV-induced CD4+ T cells also demonstrated in vitro proliferative capacity and antigen-specific production of GM-CSF, IFN-γ, and IL-13. CD8+ T-cell responses were undetectable in dengue-naive adults and low in dengue-primed individuals. B- and T-cell responses persisted up to 12 months post-vaccination in both dengue-primed and dengue-naive adults.